AT&T Earnings Perspective: Return On Invested Capital

According to Benzinga Pro, during Q2, AT&T (NYSE:T) earned $4.54 billion, a 12.14% increase from the preceding quarter. AT&T's sales decreased to $29.64 billion, a 22.21% change since Q1.

According to Benzinga Pro, during Q2, AT&T (NYSE:T) earned $4.54 billion, a 12.14% increase from the preceding quarter. AT&T’s sales decreased to $29.64 billion, a 22.21% change since Q1. AT&T earned $5.16 billion, and sales totaled $38.10 billion in Q1.

What Is ROIC?

Return on Invested Capital is a measure of yearly pre-tax profit relative to capital invested by a business. Changes in earnings and sales indicate shifts in a company’s ROIC. A higher ROIC is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROIC suggests the opposite. In Q2, AT&T posted an ROIC of 2.2%.

Keep in mind, while ROIC is a good measure of a company’s recent performance, it is not a highly reliable predictor of a company’s earnings or sales in the near future.

ROIC is a powerful metric for comparing the effectiveness of capital allocation for similar companies. A relatively high ROIC shows AT&T is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of invested capital, some of that money can be reinvested in more capital which will generally lead to higher returns and, ultimately, earnings per share (EPS) growth.

For AT&T, the positive return on invested capital ratio of 2.2% suggests that management is allocating their capital effectively. Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns.

Analyst Predictions

AT&T reported Q2 earnings per share at $0.65/share, which beat analyst predictions of $0.61/share.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Prelude Therapeutics Reports FY23 Financial Results And Outlines Key Objectives For 2024; FY23 EPS $(2.02) Vs $(2.44) YoY; Current Cash Runway Into 2026 With $232.9M In Cash, Cash Equivalents And Marketable Securities As Of December 31, 2023

First-in-class IV SMARCA2 degrader and potentially best-in-class CDK9 inhibitor on track to generate potential proof-of-concept data in 2024 Highly selective oral SMARCA2 degrader PRT7732 IND expected to be filed in

PRLD

Read More

Earnings Preview: RF Industries

RF Industries (NASDAQ:RFIL) is set to give its latest quarterly earnings report on Wednesday, 2022-09-14. Here's what investors need to know before the announcement. Analysts estimate that RF Industries will report an earnings per share (EPS) of $0.13.

RFIL